H.C. Wainwright analyst Ed Arce raised the firm’s price target on Unicycive Therapeutics (UNCY) to $7.50 from $4 and keeps a Buy rating on the shares following the Q4 report. The firm views 2025 as a “likely transformational year” for Unicycive and the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY: